aflibercept Search Results


91
BOC Sciences aflibercept
(A) Summary of NHP study design and key intraocular inflammation results. The indicated number of NHPs received bilateral intravitreal injections of <t>AAV2.aflibercept</t> or AAV2.aflibercept.io2 at 1 × 1011 vg or 5 × 1011 vg on Day 1, and intraocular inflammation was scored based on the SUN criteria system during the 12-week study. Group 6 and 7 animals received intramuscular injection of prophylactic systemic steroids on Days −1 and 6. Clinical uveitis was defined as AC or VC score of 3 or higher. A two-tailed Fisher’s Exact Test with stepdown Sidak adjustment was used to analyze number of animals that reached clinical uveitis while a two-tailed generalized linear model was used to analyze average time to reach clinical uveitis. No statistically significant differences were detected between groups. (B) Aflibercept concentrations (μg/mL) in NHP vitreous humors. Aflibercept concentrations were measured in NHP vitreous humor samples collected 12 weeks post-injection. For AAV-treated animals, animals 1 and 2 were male and animals 3 to 5 were female. For vehicle-treated animals, animal 1 was male and animals 2 and 3 were female. A univariate linear regression model with aflibercept expression as the outcome was used to compare vitreous aflibercept concentrations in vector-injected groups. No statistically significant differences were detected between groups.
Aflibercept, supplied by BOC Sciences, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/Aflibercept/pmc08409505-619-13-14
Average 91 stars, based on 1 article reviews
aflibercept - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
Eagle Biosciences aflibercept elisa kit
The 4D-150 dual-transgene expression and function in vitro. ( A ) Schema of 4D-150, a dual-transgene anti-angiogenic AAV gene therapy product. ( B ) Analysis of VEGF-A protein neutralization in the medium of human RPE transduced with 4D-150 or control R100.CAG-GFP vector, data are mean ± SD, * P < 0.05, **** P < 0.0001 by 2-way ANOVA with Tukey's multiple comparison post hoc test. ( C ) Expression of mature anti-VEGF-C miRNA measured by quantitative reverse transcription PCR (RT-qPCR) from transduced human RPE (MOI = 1000) in response to 4D-150 treatment, data are mean ± SD, ** P < 0.005 by unpaired t test. ( D ) RT-qPCR analysis of VEGF-C transcript levels in transduced RPE (MOI = 1000), normalized to Ribosomal Protein L32 as the housekeeping control. Mean ±SD. ( E ) Analysis of secreted VEGF-C protein from transduced RPE (MOI = 1000). BLQ values are represented as “0”, data are mean ± SD. **** P < 0.0001 by unpaired t test. Analysis of ( F ) proliferation and ( G ) migration of HUVEC cultures in a Transwell system after electroporation with the respective plasmid construct ( N = 3, data are mean ± SD. ** P < 0.01 compared to shock (electroporation control), * P < 0.05 compared to shock, †† P < 0.01 compared to CAG-GFP by 1-way ANOVA with Tukey's multiple comparison post hoc test. AFLB, <t>aflibercept;</t> BLQ, below the limit of quantification; GFP, green fluorescent protein; HUVEC, human umbilical vein endothelial cells; ITR, inverted terminal repeats; MOI, multiplicity of infection; RLU, relative luciferase units; RPE, retinal pigment epithelium; VEGF, vascular endothelial growth factor.
Aflibercept Elisa Kit, supplied by Eagle Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/Aflibercept+(Eyelea+%2C+Zaltrap+)+ELISA+Assay+Kit/pmc11614000-51-6-12
Average 93 stars, based on 1 article reviews
aflibercept elisa kit - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Regeneron inc aflibercept eleya
The 4D-150 dual-transgene expression and function in vitro. ( A ) Schema of 4D-150, a dual-transgene anti-angiogenic AAV gene therapy product. ( B ) Analysis of VEGF-A protein neutralization in the medium of human RPE transduced with 4D-150 or control R100.CAG-GFP vector, data are mean ± SD, * P < 0.05, **** P < 0.0001 by 2-way ANOVA with Tukey's multiple comparison post hoc test. ( C ) Expression of mature anti-VEGF-C miRNA measured by quantitative reverse transcription PCR (RT-qPCR) from transduced human RPE (MOI = 1000) in response to 4D-150 treatment, data are mean ± SD, ** P < 0.005 by unpaired t test. ( D ) RT-qPCR analysis of VEGF-C transcript levels in transduced RPE (MOI = 1000), normalized to Ribosomal Protein L32 as the housekeeping control. Mean ±SD. ( E ) Analysis of secreted VEGF-C protein from transduced RPE (MOI = 1000). BLQ values are represented as “0”, data are mean ± SD. **** P < 0.0001 by unpaired t test. Analysis of ( F ) proliferation and ( G ) migration of HUVEC cultures in a Transwell system after electroporation with the respective plasmid construct ( N = 3, data are mean ± SD. ** P < 0.01 compared to shock (electroporation control), * P < 0.05 compared to shock, †† P < 0.01 compared to CAG-GFP by 1-way ANOVA with Tukey's multiple comparison post hoc test. AFLB, <t>aflibercept;</t> BLQ, below the limit of quantification; GFP, green fluorescent protein; HUVEC, human umbilical vein endothelial cells; ITR, inverted terminal repeats; MOI, multiplicity of infection; RLU, relative luciferase units; RPE, retinal pigment epithelium; VEGF, vascular endothelial growth factor.
Aflibercept Eleya, supplied by Regeneron inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/aflibercept+eleya/pmc05727022-135-0-2
Average 90 stars, based on 1 article reviews
aflibercept eleya - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Procon GmbH aflibercept sflt01
The 4D-150 dual-transgene expression and function in vitro. ( A ) Schema of 4D-150, a dual-transgene anti-angiogenic AAV gene therapy product. ( B ) Analysis of VEGF-A protein neutralization in the medium of human RPE transduced with 4D-150 or control R100.CAG-GFP vector, data are mean ± SD, * P < 0.05, **** P < 0.0001 by 2-way ANOVA with Tukey's multiple comparison post hoc test. ( C ) Expression of mature anti-VEGF-C miRNA measured by quantitative reverse transcription PCR (RT-qPCR) from transduced human RPE (MOI = 1000) in response to 4D-150 treatment, data are mean ± SD, ** P < 0.005 by unpaired t test. ( D ) RT-qPCR analysis of VEGF-C transcript levels in transduced RPE (MOI = 1000), normalized to Ribosomal Protein L32 as the housekeeping control. Mean ±SD. ( E ) Analysis of secreted VEGF-C protein from transduced RPE (MOI = 1000). BLQ values are represented as “0”, data are mean ± SD. **** P < 0.0001 by unpaired t test. Analysis of ( F ) proliferation and ( G ) migration of HUVEC cultures in a Transwell system after electroporation with the respective plasmid construct ( N = 3, data are mean ± SD. ** P < 0.01 compared to shock (electroporation control), * P < 0.05 compared to shock, †† P < 0.01 compared to CAG-GFP by 1-way ANOVA with Tukey's multiple comparison post hoc test. AFLB, <t>aflibercept;</t> BLQ, below the limit of quantification; GFP, green fluorescent protein; HUVEC, human umbilical vein endothelial cells; ITR, inverted terminal repeats; MOI, multiplicity of infection; RLU, relative luciferase units; RPE, retinal pigment epithelium; VEGF, vascular endothelial growth factor.
Aflibercept Sflt01, supplied by Procon GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/aflibercept+sflt01/pmc07352801-242-15-17
Average 90 stars, based on 1 article reviews
aflibercept sflt01 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Synbio Technologies LLC cdna for aflibercept with a c-terminal flag tag and the same n-terminal signal peptide
The 4D-150 dual-transgene expression and function in vitro. ( A ) Schema of 4D-150, a dual-transgene anti-angiogenic AAV gene therapy product. ( B ) Analysis of VEGF-A protein neutralization in the medium of human RPE transduced with 4D-150 or control R100.CAG-GFP vector, data are mean ± SD, * P < 0.05, **** P < 0.0001 by 2-way ANOVA with Tukey's multiple comparison post hoc test. ( C ) Expression of mature anti-VEGF-C miRNA measured by quantitative reverse transcription PCR (RT-qPCR) from transduced human RPE (MOI = 1000) in response to 4D-150 treatment, data are mean ± SD, ** P < 0.005 by unpaired t test. ( D ) RT-qPCR analysis of VEGF-C transcript levels in transduced RPE (MOI = 1000), normalized to Ribosomal Protein L32 as the housekeeping control. Mean ±SD. ( E ) Analysis of secreted VEGF-C protein from transduced RPE (MOI = 1000). BLQ values are represented as “0”, data are mean ± SD. **** P < 0.0001 by unpaired t test. Analysis of ( F ) proliferation and ( G ) migration of HUVEC cultures in a Transwell system after electroporation with the respective plasmid construct ( N = 3, data are mean ± SD. ** P < 0.01 compared to shock (electroporation control), * P < 0.05 compared to shock, †† P < 0.01 compared to CAG-GFP by 1-way ANOVA with Tukey's multiple comparison post hoc test. AFLB, <t>aflibercept;</t> BLQ, below the limit of quantification; GFP, green fluorescent protein; HUVEC, human umbilical vein endothelial cells; ITR, inverted terminal repeats; MOI, multiplicity of infection; RLU, relative luciferase units; RPE, retinal pigment epithelium; VEGF, vascular endothelial growth factor.
Cdna For Aflibercept With A C Terminal Flag Tag And The Same N Terminal Signal Peptide, supplied by Synbio Technologies LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/cdna+for+aflibercept+with+a+c+terminal+flag+tag+and+the+same+n+terminal+signal+peptide/pm37509549-50-1-18
Average 90 stars, based on 1 article reviews
cdna for aflibercept with a c-terminal flag tag and the same n-terminal signal peptide - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
SAS Safety intravitreal aflibercept
The 4D-150 dual-transgene expression and function in vitro. ( A ) Schema of 4D-150, a dual-transgene anti-angiogenic AAV gene therapy product. ( B ) Analysis of VEGF-A protein neutralization in the medium of human RPE transduced with 4D-150 or control R100.CAG-GFP vector, data are mean ± SD, * P < 0.05, **** P < 0.0001 by 2-way ANOVA with Tukey's multiple comparison post hoc test. ( C ) Expression of mature anti-VEGF-C miRNA measured by quantitative reverse transcription PCR (RT-qPCR) from transduced human RPE (MOI = 1000) in response to 4D-150 treatment, data are mean ± SD, ** P < 0.005 by unpaired t test. ( D ) RT-qPCR analysis of VEGF-C transcript levels in transduced RPE (MOI = 1000), normalized to Ribosomal Protein L32 as the housekeeping control. Mean ±SD. ( E ) Analysis of secreted VEGF-C protein from transduced RPE (MOI = 1000). BLQ values are represented as “0”, data are mean ± SD. **** P < 0.0001 by unpaired t test. Analysis of ( F ) proliferation and ( G ) migration of HUVEC cultures in a Transwell system after electroporation with the respective plasmid construct ( N = 3, data are mean ± SD. ** P < 0.01 compared to shock (electroporation control), * P < 0.05 compared to shock, †† P < 0.01 compared to CAG-GFP by 1-way ANOVA with Tukey's multiple comparison post hoc test. AFLB, <t>aflibercept;</t> BLQ, below the limit of quantification; GFP, green fluorescent protein; HUVEC, human umbilical vein endothelial cells; ITR, inverted terminal repeats; MOI, multiplicity of infection; RLU, relative luciferase units; RPE, retinal pigment epithelium; VEGF, vascular endothelial growth factor.
Intravitreal Aflibercept, supplied by SAS Safety, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/intravitreal+aflibercept/pm36309572-94-12-15
Average 90 stars, based on 1 article reviews
intravitreal aflibercept - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Regeneron inc ocular medication aflibercept eylea
Price change of <t>aflibercept</t> by country and external reference pricing status Source : Authors’ analysis of data from the Pricentric ONE™ database (Eversana, Chicago, IL).
Ocular Medication Aflibercept Eylea, supplied by Regeneron inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/ocular+medication+aflibercept+eylea/pmc10297733-190-3-7
Average 90 stars, based on 1 article reviews
ocular medication aflibercept eylea - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Regeneron inc aflibercept eylea
Price change of <t>aflibercept</t> by country and external reference pricing status Source : Authors’ analysis of data from the Pricentric ONE™ database (Eversana, Chicago, IL).
Aflibercept Eylea, supplied by Regeneron inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/aflibercept+eylea/pm37631054-244-0-5
Average 90 stars, based on 1 article reviews
aflibercept eylea - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Regeneron inc anti-vegf agents aflibercept eylea
Price change of <t>aflibercept</t> by country and external reference pricing status Source : Authors’ analysis of data from the Pricentric ONE™ database (Eversana, Chicago, IL).
Anti Vegf Agents Aflibercept Eylea, supplied by Regeneron inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/anti+vegf+agents+aflibercept+eylea/10__1097_slash_md__0000000000006406-25-10-12
Average 90 stars, based on 1 article reviews
anti-vegf agents aflibercept eylea - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Regeneron inc aflibercept
Price change of <t>aflibercept</t> by country and external reference pricing status Source : Authors’ analysis of data from the Pricentric ONE™ database (Eversana, Chicago, IL).
Aflibercept, supplied by Regeneron inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/aflibercept/pm39198703-234-37-30
Average 90 stars, based on 1 article reviews
aflibercept - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Regeneron inc aflibercept (eylea
Diagram showing the structure of the vascular endothelial growth factor receptor-1 and -2 and the structure of <t>aflibercept</t> (VEGF Trap-eye). Notes: Aflibercept (VEGF Trap-eye) is generated by a fusion that includes the second binding domain of vascular endothelial growth factor receptor (VEGFR)-1 and the third binding domain of VEGFR-2 attached to a FC fragment of a human IgG. Abbreviation: FC, fragment crystallizable region.
Aflibercept (Eylea, supplied by Regeneron inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/aflibercept++eylea+antibody/pmc03749085-5-0-2
Average 90 stars, based on 1 article reviews
aflibercept (eylea - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Regeneron inc aflibercept (vegf trap, registered trademark
Diagram showing the structure of the vascular endothelial growth factor receptor-1 and -2 and the structure of <t>aflibercept</t> (VEGF Trap-eye). Notes: Aflibercept (VEGF Trap-eye) is generated by a fusion that includes the second binding domain of vascular endothelial growth factor receptor (VEGFR)-1 and the third binding domain of VEGFR-2 attached to a FC fragment of a human IgG. Abbreviation: FC, fragment crystallizable region.
Aflibercept (Vegf Trap, Registered Trademark, supplied by Regeneron inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aflibercept/aflibercept+vegf+trap/us08710187-222-42-49
Average 90 stars, based on 1 article reviews
aflibercept (vegf trap, registered trademark - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


(A) Summary of NHP study design and key intraocular inflammation results. The indicated number of NHPs received bilateral intravitreal injections of AAV2.aflibercept or AAV2.aflibercept.io2 at 1 × 1011 vg or 5 × 1011 vg on Day 1, and intraocular inflammation was scored based on the SUN criteria system during the 12-week study. Group 6 and 7 animals received intramuscular injection of prophylactic systemic steroids on Days −1 and 6. Clinical uveitis was defined as AC or VC score of 3 or higher. A two-tailed Fisher’s Exact Test with stepdown Sidak adjustment was used to analyze number of animals that reached clinical uveitis while a two-tailed generalized linear model was used to analyze average time to reach clinical uveitis. No statistically significant differences were detected between groups. (B) Aflibercept concentrations (μg/mL) in NHP vitreous humors. Aflibercept concentrations were measured in NHP vitreous humor samples collected 12 weeks post-injection. For AAV-treated animals, animals 1 and 2 were male and animals 3 to 5 were female. For vehicle-treated animals, animal 1 was male and animals 2 and 3 were female. A univariate linear regression model with aflibercept expression as the outcome was used to compare vitreous aflibercept concentrations in vector-injected groups. No statistically significant differences were detected between groups.

Journal: Science translational medicine

Article Title: Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses

doi: 10.1126/scitranslmed.abd3438

Figure Lengend Snippet: (A) Summary of NHP study design and key intraocular inflammation results. The indicated number of NHPs received bilateral intravitreal injections of AAV2.aflibercept or AAV2.aflibercept.io2 at 1 × 1011 vg or 5 × 1011 vg on Day 1, and intraocular inflammation was scored based on the SUN criteria system during the 12-week study. Group 6 and 7 animals received intramuscular injection of prophylactic systemic steroids on Days −1 and 6. Clinical uveitis was defined as AC or VC score of 3 or higher. A two-tailed Fisher’s Exact Test with stepdown Sidak adjustment was used to analyze number of animals that reached clinical uveitis while a two-tailed generalized linear model was used to analyze average time to reach clinical uveitis. No statistically significant differences were detected between groups. (B) Aflibercept concentrations (μg/mL) in NHP vitreous humors. Aflibercept concentrations were measured in NHP vitreous humor samples collected 12 weeks post-injection. For AAV-treated animals, animals 1 and 2 were male and animals 3 to 5 were female. For vehicle-treated animals, animal 1 was male and animals 2 and 3 were female. A univariate linear regression model with aflibercept expression as the outcome was used to compare vitreous aflibercept concentrations in vector-injected groups. No statistically significant differences were detected between groups.

Article Snippet: A standard curve was prepared for each run on each plate using purified aflibercept (BOC Sciences, CAS 862111-32-8) of known concentration diluted in cynomolgus macaque vitreous humor (BioIVT).

Techniques: Injection, Two Tailed Test, Expressing, Plasmid Preparation

The 4D-150 dual-transgene expression and function in vitro. ( A ) Schema of 4D-150, a dual-transgene anti-angiogenic AAV gene therapy product. ( B ) Analysis of VEGF-A protein neutralization in the medium of human RPE transduced with 4D-150 or control R100.CAG-GFP vector, data are mean ± SD, * P < 0.05, **** P < 0.0001 by 2-way ANOVA with Tukey's multiple comparison post hoc test. ( C ) Expression of mature anti-VEGF-C miRNA measured by quantitative reverse transcription PCR (RT-qPCR) from transduced human RPE (MOI = 1000) in response to 4D-150 treatment, data are mean ± SD, ** P < 0.005 by unpaired t test. ( D ) RT-qPCR analysis of VEGF-C transcript levels in transduced RPE (MOI = 1000), normalized to Ribosomal Protein L32 as the housekeeping control. Mean ±SD. ( E ) Analysis of secreted VEGF-C protein from transduced RPE (MOI = 1000). BLQ values are represented as “0”, data are mean ± SD. **** P < 0.0001 by unpaired t test. Analysis of ( F ) proliferation and ( G ) migration of HUVEC cultures in a Transwell system after electroporation with the respective plasmid construct ( N = 3, data are mean ± SD. ** P < 0.01 compared to shock (electroporation control), * P < 0.05 compared to shock, †† P < 0.01 compared to CAG-GFP by 1-way ANOVA with Tukey's multiple comparison post hoc test. AFLB, aflibercept; BLQ, below the limit of quantification; GFP, green fluorescent protein; HUVEC, human umbilical vein endothelial cells; ITR, inverted terminal repeats; MOI, multiplicity of infection; RLU, relative luciferase units; RPE, retinal pigment epithelium; VEGF, vascular endothelial growth factor.

Journal: Investigative Ophthalmology & Visual Science

Article Title: Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies

doi: 10.1167/iovs.65.14.1

Figure Lengend Snippet: The 4D-150 dual-transgene expression and function in vitro. ( A ) Schema of 4D-150, a dual-transgene anti-angiogenic AAV gene therapy product. ( B ) Analysis of VEGF-A protein neutralization in the medium of human RPE transduced with 4D-150 or control R100.CAG-GFP vector, data are mean ± SD, * P < 0.05, **** P < 0.0001 by 2-way ANOVA with Tukey's multiple comparison post hoc test. ( C ) Expression of mature anti-VEGF-C miRNA measured by quantitative reverse transcription PCR (RT-qPCR) from transduced human RPE (MOI = 1000) in response to 4D-150 treatment, data are mean ± SD, ** P < 0.005 by unpaired t test. ( D ) RT-qPCR analysis of VEGF-C transcript levels in transduced RPE (MOI = 1000), normalized to Ribosomal Protein L32 as the housekeeping control. Mean ±SD. ( E ) Analysis of secreted VEGF-C protein from transduced RPE (MOI = 1000). BLQ values are represented as “0”, data are mean ± SD. **** P < 0.0001 by unpaired t test. Analysis of ( F ) proliferation and ( G ) migration of HUVEC cultures in a Transwell system after electroporation with the respective plasmid construct ( N = 3, data are mean ± SD. ** P < 0.01 compared to shock (electroporation control), * P < 0.05 compared to shock, †† P < 0.01 compared to CAG-GFP by 1-way ANOVA with Tukey's multiple comparison post hoc test. AFLB, aflibercept; BLQ, below the limit of quantification; GFP, green fluorescent protein; HUVEC, human umbilical vein endothelial cells; ITR, inverted terminal repeats; MOI, multiplicity of infection; RLU, relative luciferase units; RPE, retinal pigment epithelium; VEGF, vascular endothelial growth factor.

Article Snippet: Free aflibercept was evaluated using the aflibercept ELISA kit (Cat. No. IG-AA115; Eagle Biosciences, Nashua, NH, USA).

Techniques: Expressing, In Vitro, Neutralization, Transduction, Control, Plasmid Preparation, Comparison, Reverse Transcription, Quantitative RT-PCR, Migration, Electroporation, Construct, Infection, Luciferase

Aflibercept protein expression and laser-induced CNV lesions in primates following IVT administration of 4D-150 or control. ( A ) Secreted free aflibercept protein expression in the aqueous humor by treatment group 21 days post IVT administration ( n = 14 eyes per group) and prior to laser-induced CNV, data are mean ± SD. **** P < 0.0001 by 1-way ANOVA with Bonferroni's multiple comparisons. ( B ) Percentage of eyes with grade IV lesions 2 weeks post laser per treatment group. ** P < 0.005, * P < 0.01 compared to vehicle by Fisher's Exact Prob test. ( C ) Reduced CNV complex area with 4D-150 pretreatment at 4 weeks post laser. Data are mean ± SEM. CNV complex areas of the principal axis of each lesion were calculated for each treatment group. Pretreatment with all doses of 4D-150 resulted in significantly smaller mean CNV complex areas compared to vehicle. ** P < 0.005 by 2-way ANOVA followed by Tukey-Kramer HSD. AFLB, aflibercept; CNV, choroidal neovascularization; IVT, intravitreal.

Journal: Investigative Ophthalmology & Visual Science

Article Title: Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies

doi: 10.1167/iovs.65.14.1

Figure Lengend Snippet: Aflibercept protein expression and laser-induced CNV lesions in primates following IVT administration of 4D-150 or control. ( A ) Secreted free aflibercept protein expression in the aqueous humor by treatment group 21 days post IVT administration ( n = 14 eyes per group) and prior to laser-induced CNV, data are mean ± SD. **** P < 0.0001 by 1-way ANOVA with Bonferroni's multiple comparisons. ( B ) Percentage of eyes with grade IV lesions 2 weeks post laser per treatment group. ** P < 0.005, * P < 0.01 compared to vehicle by Fisher's Exact Prob test. ( C ) Reduced CNV complex area with 4D-150 pretreatment at 4 weeks post laser. Data are mean ± SEM. CNV complex areas of the principal axis of each lesion were calculated for each treatment group. Pretreatment with all doses of 4D-150 resulted in significantly smaller mean CNV complex areas compared to vehicle. ** P < 0.005 by 2-way ANOVA followed by Tukey-Kramer HSD. AFLB, aflibercept; CNV, choroidal neovascularization; IVT, intravitreal.

Article Snippet: Free aflibercept was evaluated using the aflibercept ELISA kit (Cat. No. IG-AA115; Eagle Biosciences, Nashua, NH, USA).

Techniques: Expressing, Control

Price change of aflibercept by country and external reference pricing status Source : Authors’ analysis of data from the Pricentric ONE™ database (Eversana, Chicago, IL).

Journal: Health Policy OPEN

Article Title: The impact of external reference pricing on pharmaceutical costs and market dynamics

doi: 10.1016/j.hpopen.2023.100093

Figure Lengend Snippet: Price change of aflibercept by country and external reference pricing status Source : Authors’ analysis of data from the Pricentric ONE™ database (Eversana, Chicago, IL).

Article Snippet: For example, the ocular medication aflibercept (Eylea®, Regeneron Pharmaceuticals, Inc., US) had annual price declines of $23 per unit on average in ERP dyads, whereas prices increased by $30 per unit in non-ERP dyads , although this varied by setting and region.

Techniques:

Diagram showing the structure of the vascular endothelial growth factor receptor-1 and -2 and the structure of aflibercept (VEGF Trap-eye). Notes: Aflibercept (VEGF Trap-eye) is generated by a fusion that includes the second binding domain of vascular endothelial growth factor receptor (VEGFR)-1 and the third binding domain of VEGFR-2 attached to a FC fragment of a human IgG. Abbreviation: FC, fragment crystallizable region.

Journal: Drug Design, Development and Therapy

Article Title: Aflibercept in wet AMD: specific role and optimal use

doi: 10.2147/DDDT.S40215

Figure Lengend Snippet: Diagram showing the structure of the vascular endothelial growth factor receptor-1 and -2 and the structure of aflibercept (VEGF Trap-eye). Notes: Aflibercept (VEGF Trap-eye) is generated by a fusion that includes the second binding domain of vascular endothelial growth factor receptor (VEGFR)-1 and the third binding domain of VEGFR-2 attached to a FC fragment of a human IgG. Abbreviation: FC, fragment crystallizable region.

Article Snippet: Aflibercept (EYLEA®; Regeneron Pharmaceutical Inc and Bayer), also named VEGF Trap-eye, is the most recent member of the anti-VEGF armamentarium that was approved by the US Food and Drug Administration in November 2011.

Techniques: Generated, Binding Assay

Vascular endothelial growth factor binds to two vascular endothelial growth factor receptors which induces the angiogenic response by activating the tyrosine kinase. Notes: vascular endothelial growth factor receptor (VEGFR)-2 is shown. Aflibercept (VEGF Trap-eye) binds all vascular endothelial growth factor (VEGF) isoforms more tightly than their native receptors, thus preventing binding of VEGF to its cognate receptors.

Journal: Drug Design, Development and Therapy

Article Title: Aflibercept in wet AMD: specific role and optimal use

doi: 10.2147/DDDT.S40215

Figure Lengend Snippet: Vascular endothelial growth factor binds to two vascular endothelial growth factor receptors which induces the angiogenic response by activating the tyrosine kinase. Notes: vascular endothelial growth factor receptor (VEGFR)-2 is shown. Aflibercept (VEGF Trap-eye) binds all vascular endothelial growth factor (VEGF) isoforms more tightly than their native receptors, thus preventing binding of VEGF to its cognate receptors.

Article Snippet: Aflibercept (EYLEA®; Regeneron Pharmaceutical Inc and Bayer), also named VEGF Trap-eye, is the most recent member of the anti-VEGF armamentarium that was approved by the US Food and Drug Administration in November 2011.

Techniques: Binding Assay